Lisata Therapeutics (NASDAQ:LSTA) Issues Quarterly Earnings Results

Lisata Therapeutics (NASDAQ:LSTA) announced its quarterly earnings data on Friday. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.39, FiscalAI reports.

Lisata Therapeutics Stock Performance

Shares of NASDAQ LSTA traded down $0.04 during trading on Friday, hitting $1.25. 104,784 shares of the company traded hands, compared to its average volume of 184,345. Lisata Therapeutics has a fifty-two week low of $0.96 and a fifty-two week high of $5.07. The firm has a market capitalization of $13.45 million, a price-to-earnings ratio of -0.76 and a beta of 1.04. The business’s fifty day moving average is $1.29 and its 200 day moving average is $2.89.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Reduce”.

About Lisata Therapeutics

Lisata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to improve the delivery and effectiveness of cancer treatments by targeting the tumor microenvironment, which can limit the penetration of medicines into tumors. Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is a tumor-penetrating peptide intended to selectively home to tumor tissue and temporarily modify the tumor microenvironment, potentially helping co-administered anticancer therapies reach cancer cells more effectively.